Corrigendum: Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2018) 29 (iv238–iv255) DOI: 10.1093/annonc/mdy308);Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 29, Issue , 2018, Pages iv238-iv255

  Vogel, A ^a   Cervantes, A ^b   Chau, I ^c   Daniele, B ^d   Llovet, J ^e,f,g   Meyer, T ^h,i   Nault, J C ^j   Neumann, U ^k   Ricke, J ^l   Sangro, B ^m   Schirmacher, P ⁿ   Verslype, C ^o   Zech, C J ^p   Arnold, D ^q   Martinelli, E ^r  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF VALENCIA   (Spain)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d Direttore Dipartimento di Oncologia e UOC Oncologia Medica AO   (Italy)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF BARCELONA   (Spain)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^h ROYAL FREE HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j HÔPITAL JEAN VERDIER   (France)

^k RWTH AACHEN UNIVERSITY   (Germany)

^l UNIVERSITY OF MUNICH   (Germany)

^m UNIVERSITY CLINIC OF NAVARRA   (Spain)

ⁿ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p UNIVERSITY OF BASEL   (Switzerland)

^q ASKLEPIOS KLINIK ALTONA   (Germany)

^r SECOND UNIVERSITY OF NAPLES   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BATABULIN; CABOZANTINIB; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; INTERFERON; IODINATED POPPYSEED OIL; LENVATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOMYCIN; NIVOLUMAB; NOLATREXED; OXALIPLATIN; PEMBROLIZUMAB; RAMUCIRUMAB; RAPAMYCIN; REGORAFENIB; SORAFENIB; YTTRIUM 90; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CHEMOEMBOLIZATION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; EARLY CANCER; FOLLOW UP; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; IMMUNOSURVEILLANCE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MICROWAVE THERMOTHERAPY; MOLECULAR PATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SELECTIVE INTERNAL RADIOTHERAPY; STEREOTACTIC BODY RADIATION THERAPY; TUMOR BIOPSY; ABLATION THERAPY; AFTERCARE; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; EARLY CANCER DIAGNOSIS; EUROPE; FATTY LIVER; GENETICS; INCIDENCE; LIVER; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TUMOR; MASS SCREENING; MEDICAL SOCIETY; ONCOLOGY; PATHOLOGY; PROCEDURES; RADIOSURGERY; SURGERY; SURVIVORSHIP; TREATMENT OUTCOME;

ABLATION TECHNIQUES; AFTERCARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; EUROPE; FATTY LIVER; HEPATECTOMY; HUMANS; INCIDENCE; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MASS SCREENING; MEDICAL ONCOLOGY; NEOPLASM STAGING; PRECISION MEDICINE; RADIOSURGERY; RISK ASSESSMENT; SOCIETIES, MEDICAL; SURVIVORSHIP; TREATMENT OUTCOME;

EID: 85054346991     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy510     Document Type: Erratum

References (139)

1. Petrick JL, Kelly SP, Altekruse SF et al. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol 2016; 34: 1787-1794.
2. White DL, Thrift AP, Kanwal F et al. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology 2017; 152: 812-820. e5.
3. Globoscan. http://globocan. iarc. fr/old/FactSheets/cancers/liver-new. asp
4. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: e359-e386.
5. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859.
6. Papatheodoridis GV, Dalekos GN, Yurdaydin C et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 2015; 62: 363-370.
7. Cardoso AC, Moucari R, Figueiredo-Mendes C et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-657.
8. Waziry R, Hajarizadeh B, Grebely J et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 2017; 67: 1204-1212.
9. Yatsuji S, Hashimoto E, Tobari M et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248-254.
10. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.
11. Noureddin M, Rinella ME. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis 2015; 19: 361-379.
12. Paradis V, Zalinski S, Chelbi E et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859.
13. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001; 96: 2462-2467.
14. Marrero JA, Fontana RJ, Fu S et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005; 42: 218-224.
15. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101: 422-434.
16. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
17. Sato T, Tateishi R, Yoshida H et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int 2009; 3: 544-550.
18. Singal A, Volk ML, Waljee A et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.
19. Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999; 6: 108-110.
20. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422.
21. Trinchet JC, Chaffaut C, Bourcier V et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3-and 6-month periodicities. Hepatology 2011; 54: 1987-1997.
22. Matsui O, Kobayashi S, Sanada J et al. Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 2011; 36: 264-272.
23. Forner A, Vilana R, Ayuso C et al. Diagnosis of hepatic nodules 20mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104.
24. Lee YJ, Lee JM, Lee JS et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015; 275: 97-109.
25. Ye F, Liu J, Ouyang H. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore) 2015; 94: e1157.
26. Hanna RF, Miloushev VZ, Tang A et al. Comparative 13-year metaanalysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY) 2016; 41: 71-90.
27. Tang A, Bashir MR, Corwin MT et al. Evidence supporting LI-RADS major features for CT-and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 2018; 286: 29-48.
28. Kumada T, Toyoda H, Tada T et al. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 2011; 197: 58-63.
29. Golfieri R, Grazioli L, Orlando E et al. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. J Magn Reson Imaging 2012; 36: 648-657.
30. Bartolozzi C, Battaglia V, Bargellini I et al. Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging 2013; 38: 290-296.
31. Yoon JH, Lee JM, Yang HK et al. Non-hypervascular hypointense nodules >/1/41 cm on the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging in cirrhotic livers. Dig Dis 2014; 32: 678-689.
32. Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 2015; 61: 1056-1065.
33. CT/MRI LI-RADSVR v2018. https://www. acr. org/-/media/ACR/Files/ RADS/LI-RADS/LI-RADS-2018-Core. pdf? la1/4en
34. Khalili K, Kim TK, Jang HJ et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011; 54: 723-728.
35. Wildner D, Bernatik T, Greis C et al. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients-early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med 2015; 36: 132-139.
36. Terzi E, Iavarone M, Pompili M et al. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1, 006 nodules. J Hepatol 2018; 68: 485-492.
37. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-664.
38. Sciarra A, Di Tommaso L, Nakano M et al. Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications. J Hepatol 2016; 64: 87-93.
39. Calderaro J, Couchy G, Imbeaud S et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 2017; 67: 727-738.
40. Yeh MM, Liu Y, Torbenson M. Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study. Hum Pathol 2015; 46: 1769-1775.
41. Silva MA, Hegab B, Hyde C et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57: 1592-1596.
42. Fuks D, Cauchy F, Fusco G et al. Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC. J Hepatol 2014; 61: 589-593.
43. Rockey DC, Caldwell SH, Goodman ZD et al. Liver biopsy. Hepatology 2009; 49: 1017-1044.
44. Witjes CD, Verhoef C, Kwekkeboom DJ et al. Is bone scintigraphy indicated in surgical work-up for hepatocellular carcinoma patients? J Surg Res 2013; 181: 256-261.
45. Boussouar S, Itti E, Lin SJ et al. Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and (18)F-FDG PET/CT in patients on waiting-list for liver transplantation. Cancer Imaging 2016; 16: 4.
46. Hyun SH, Eo JS, Song BI et al. Preoperative prediction of microvascular invasion of hepatocellular carcinoma using 18F-FDG PET/CT: a multicenter retrospective cohort study. Eur J Nucl Med Mol Imaging 2018; 45: 720-726.
47. Johnson PJ, Berhane S, Kagebayashi C et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33: 550-558.
48. Augustin S, Pons M, Maurice JB et al. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology 2017; 66: 1980-1988.
49. Brierley JD, Gospodarowicz MK, Wittekind C (eds). IUCC TNM Classification of Malignant Tumours, 8th edition. Oxford: John Wiley & Sons Inc. 2016.
50. Kamarajah SK, Frankel TL, Sonnenday C et al. Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with hepatocellular carcinoma (HCC): a Surveillance, Epidemiology, End Results (SEER) analysis. J Surg Oncol 2018; 117: 644-650.
51. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391: 1301-1314.
52. Cucchetti A, Ercolani G, Vivarelli M et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg 2009; 250: 922-928.
53. Berzigotti A, Reig M, Abraldes JG et al. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 2015; 61: 526-536.
54. Fancellu A, Rosman AS, Sanna V et al. Meta-analysis of trials comparing minimally-invasive and open liver resections for hepatocellular carcinoma. J Surg Res 2011; 171: e33-e45.
55. Yuki K, Hirohashi S, Sakamoto M et al. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 1990; 66: 2174-2179.
56. Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356: 1545-1559.
57. Cucchetti A, Cescon M, Ercolani G et al. A comprehensive metaregression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 3697-3705.
58. Zhou Y, Xu D, Wu L, Li B. Meta-analysis of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. Langenbecks Arch Surg 2011; 396: 1109-1117.
59. Rahbari NN, Mehrabi A, Mollberg NM et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011; 253: 453-469.
60. Clavien PA, Lesurtel M, Bossuyt PM et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22.
61. Yao FY, Xiao L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7: 2587-2596.
62. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
63. Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008; 8: 1982-1989.
64. Cucchetti A, Piscaglia F, Cescon M et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013; 59: 300-307.
65. Geissler EK, Schnitzbauer AA, Zulke C et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation 2016; 100: 116-125.
66. Bruix J, Takayama T, Mazzaferro V et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16: 1344-1354.
67. Hasegawa K, Kokudo N, Makuuchi M et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013; 58: 724-729.
68. Chen MS, Li JQ, Zheng Y et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328.
69. Huang J, Yan L, Cheng Z et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252: 903-912.
70. Feng K, Yan J, Li X et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57: 794-802.
71. Jiang B, Yan XF, Zhang JH. Meta-analysis of laparoscopic versus open liver resection for hepatocellular carcinoma. Hepatol Res 2018; 48: 635-663.
72. Lin ZZ, Shau WY, Hsu C et al. Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One 2013; 8: e80276.
73. Germani G, Pleguezuelo M, Gurusamy K et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010; 52: 380-388.
74. Zeng ZC, Seong J, Yoon SM et al. Consensus on stereotactic body radiation therapy for small-sized hepatocellular carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Liver Cancer 2017; 6: 264-274.
75. Denecke T, Stelter L, Schnapauff D et al. CT-guided interstitial brachytherapy of hepatocellular carcinoma before liver transplantation: an equivalent alternative to transarterial chemoembolization? Eur Radiol 2015; 25: 2608-2616.
76. Mohnike K, Wieners G, Schwartz F et al. Computed tomographyguided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010; 78: 172-179.
77. Collettini F, Schreiber N, Schnapauff D et al. CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma. Strahlenther Onkol 2015; 191: 405-412.
78. Rajyaguru DJ, Borgert AJ, Smith AL et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database. J Clin Oncol 2018; 36: 600-608.
79. Brinkhaus G, Lock JF, Malinowski M et al. CT-guided high-dose-rate brachytherapy of liver tumours does not impair hepatic function and shows high overall safety and favourable survival rates. Ann Surg Oncol 2014; 21: 4284-4292.
80. Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis and systematic review. Radiother Oncol 2018 [Epub ahead of print].
81. Sangro B, Salem R. Transarterial chemoembolization and radioembolization. Semin Liver Dis 2014; 34: 435-443.
82. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
83. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739.
84. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
85. Golfieri R, Giampalma E, Renzulli M et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111: 255-264.
86. Burrel M, Reig M, Forner A et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 2012; 56: 1330-1335.
87. Malagari K, Pomoni M, Moschouris H et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: fiveyear survival analysis. Cardiovasc Intervent Radiol 2012; 35: 1119-1128.
88. Kadalayil L, Benini R, Pallan L et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013; 24: 2565-2570.
89. Sieghart W, Hucke F, Pinter M et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013; 57: 2261-2273.
90. Hucke F, Sieghart W, Pinter M et al. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol 2014; 60: 118-126.
91. Kirstein MM, Schweitzer N, Ay N et al. Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization. Scand J Gastroenterol 2017; 52: 116-124.
92. Meyer T, Fox R, Ma YT et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2: 565-575.
93. Waked I, Berhane S, Toyoda H et al. Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br J Cancer 2017; 116: 448-454.
94. Lammer J, Malagari K, Vogl T et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
95. Meyer T, Kirkwood A, Roughton M et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 2013; 108: 1252-1259.
96. Brown KT, Do RK, Gonen M et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 2016; 34: 2046.
97. Malagari K, Pomoni M, Kelekis A et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33: 541-551.
98. Kudo M, Cheng AL, Park JW et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol 2018; 3: 37-46.
99. Kudo M, Han G, Finn RS et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology 2014; 60: 1697-1707.
100. KudoM, Imanaka K, Chida N et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47: 2117-2127.
101. Lencioni R, Llovet JM, Han G et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 2016; 64: 1090-1098.
102. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013; 58: 2188-2197.
103. Chow PKH, Gandhi M, Tan SB et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 2018; 36: 1913-1921.
104. Vilgrain V, Pereira H, Assenat E et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18: 1624-1636.
105. Ricke J, Sangro B, Amthauer H et al. The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the Soramic trial palliative cohort. J Hepatol 2018; 68(Suppl 1): S102.
106. Salem R, Gordon AC, Mouli S et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016; 151: 115-1163. e2.
107. Salem R, Lewandowski RJ, Kulik L et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497-507. e2.
108. Riaz A, Gabr A, Abouchaleh N et al. Radioembolization for hepatocellular carcinoma: statistical confirmation of improved survival in responders by landmark analyses. Hepatology 2018; 67: 873-883.
109. Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 2015; 12: 436.
110. Yeo W, Mok TS, Zee B et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-1538.
111. Gish RG, Porta C, Lazar L et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007; 25: 3069-3075.
112. Qin S, Bai Y, Lim HY et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013; 31: 3501-3508.
113. Abou-Alfa GK, Johnson P, Knox JJ et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304: 2154-2160.
114. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
115. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
116. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
117. Bruix J, Cheng AL, Meinhardt G et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol 2017; 67: 999-1008.
118. Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391: 1163-1173.
119. Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56-66.
120. Abou-Alfa GK, Meyer T, Cheng AL et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial. J Clin Oncol 2018; 36(Suppl 4): 207.
121. Zhu AX, Kang Y-K, Yen C-J et al. REACH-2: a randomized, doubleblind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol 2018; 36: 4003-4003.
122. Sangro B, Gomez-Martin C, de la MataMet al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013; 59: 81-88.
123. El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389: 2492-2502.
124. Zhu AX, Finn RS, Edeline J et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19: 940-952.
125. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015; 149: 1226-1239. e4.
126. Rimassa L, Assenat E, Peck-Radosavljevic M et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebocontrolled study. Lancet Oncol 2018; 19: 682-693.
127. Gillmore R, Stuart S, Kirkwood A et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55: 1309-1316.
128. Shim JH, Lee HC, Kim SO et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012; 262: 708-718.
129. Vincenzi B, Di Maio M, Silletta M et al. Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS One 2015; 10: e0133488.
130. Prajapati HJ, Spivey JR, Hanish SI et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 2013; 24: 965-973.
131. Lencioni R, Montal R, Torres F et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol 2017; 66: 1166-1172.
132. Meyer T, Palmer DH, Cheng AL et al. mRECIST to predict survival in advanced hepatocellular carcinoma: analysis of two randomised phase II trials comparing nintedanib vs sorafenib. Liver Int 2017; 37: 1047-1055.
133. Semaan S, Makkar J, Lewis S et al. Imaging of hepatocellular carcinoma response after 90Y radioembolization. AJR Am J Roentgenol 2017; 209: w263-w276.
134. Vouche M, Kulik L, Atassi R et al. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: imaging analysis from a prospective randomized trial of Y90 6 sorafenib. Hepatology 2013; 58: 1655-1666.
135. Mamdani H, Wu H, O'Neil BH, Sehdev A. Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature. Discov Med 2017; 23: 331-336.
136. Seymour L, Bogaerts J, Perrone A et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143-e152.
137. Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 2010; 33: 11-17.
138. Sasaki Y, Yamada T, Tanaka H et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B-or hepatitis C-related hepatocellular carcinoma. Ann Surg 2006; 244: 771-780.
139. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.